We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Prevails in Antitrust Suits Over Leukemia Drug
Novartis Prevails in Antitrust Suits Over Leukemia Drug
A federal appeals court affirmed last week that Novartis did not engage in antitrust violations to protect a patent on its leukemia drug Gleevec (imatinib).